An observational study in Sarcopenia, Cancer and Critical Illness, sponsored by Hospital H+ Queretaro. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Hospital H+ Queretaro · Observational
Among 10 studies in Sarcopenia with a site in Mexico — 3 open to participants now, 4 under way, none of them phase 3. Sarcopenia · Mexico.
Among the 10 studies in Sarcopenia with a site in Mexico, this one is one of 3 that started in 2026, is one of 3 observational ones, and was the 8th registered.
1,329 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.
Browse Sarcopenia studies →3 of the 10 studies in Sarcopenia with a site in Mexico are open now. Recruiting first, the newest first:
Instituto Nacional de Cancerologia de Mexico · Sites in Mexico
Ages 18–70
Instituto Nacional de Cancerologia de Mexico · Sites in Mexico
Ages 18+
JULIO GRANADOS MONTIEL · Sites in Mexico
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 246 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 33 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 29 across the 7 interventional studies, 30 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 9 most frequent:
Hospital H+ Queretaro is the lead sponsor of 13 studies on the registry; 6 are open to participants now.
Hospital H+ Queretaro has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
4 of the studies in Sarcopenia with a site in Mexico that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02734069Instituto Nacional de Cancerologia de MexicoImpact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC | 2026-12 |
| NCT02978521Instituto Nacional de Cancerologia de MexicoPulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients | 2026-12-05 |
| NCT07877545Centenario Hospital Miguel HidalgoEgg Albumin and Agave Fructans With Exercise in Hemodialysis | 2027-02-03 |
| NCT07567378JULIO GRANADOS MONTIELCARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Sarcopenia with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the association between computed tomography-determined sarcopenia and muscle quality impairment with 28-day mortality in adult patients (aged 18 and older) with solid or hematologic malignancies admitted to the Intensive Care Unit (ICU).
The main question it aims to answer is: Is lower psoas muscle quality, calculated using the Hounsfield Unit Average Calculation (HUAC), associated with increased 28-day mortality in critically ill cancer patients? Researchers will compare patients who survived at 28 days with those who died to evaluate whether tomographic muscle measurements (HUAC and total psoas area) and clinical nutritional scores (mNUTRIC) differ between groups and predict mortality.
Participants' records will be evaluated through:
Critically ill adult cancer patients (with solid or hematological malignancies) admitted to the Intensive Care Unit (ICU) at Hospital H+ Querétaro between January 2022 and December 2025 who underwent abdominal CT scans during routine clinical management
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Critically ill cancer patients admitted to the ICU who survived at 28 days post-admission.
Other: Computed Tomography Muscle Assessment (HUAC)
Critically ill cancer patients admitted to the ICU who died within 28 days post-admission
Other: Computed Tomography Muscle Assessment (HUAC)
Quantitative measurement of cross-sectional area and radiological density (Hounsfield Units) of the bilateral psoas muscles on abdominal CT scans obtained during routine care to calculate the Hounsfield Unit Average Calculation (HUAC).
28-Day All-Cause Mortality
Vital status (alive or deceased) of critically ill cancer patients evaluated at 28 days following their admission to the Intensive Care Unit (ICU). The association with muscle quality metrics, specifically the Hounsfield Unit Average Calculation (HUAC) of the psoas muscles obtained via computed tomography (CT) scan, will be assessed.
Time frame: At 28 days post-ICU admission
Nutritional Risk Assessment via mNUTRIC Score
Evaluation of nutritional risk upon ICU admission using the modified Nutrition Risk in Critically Ill (mNUTRIC) score. The score ranges from 0 to 9 points, where 0 represents the lowest nutritional risk and 9 represents the highest nutritional risk (higher scores indicate a worse outcome/higher nutritional risk; a score \> 5 indicates high nutritional risk).
Time frame: Baseline (at ICU admission)
Total Psoas Muscle Cross-Sectional Area
Quantitative measurement of the total cross-sectional area of the right and left psoas muscles combined (mm\^2 or cm\^2) derived from abdominal computed tomography (CT) scans to assess muscle mass quantity.
Time frame: Baseline (CT scans performed within routine care prior to or at ICU admission)
Acute Physiology and Chronic Health Evaluation II (APACHE II) Score
Assessment of clinical disease severity at ICU admission using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score. The score ranges from 0 to 71 points, where 0 indicates no physiological impairment and 71 represents the most severe degree of illness (higher scores indicate greater disease severity and a higher risk of mortality).
Time frame: At ICU admission (Baseline)
Sequential Organ Failure Assessment (SOFA) Score
Assessment of organ dysfunction at ICU admission using the Sequential Organ Failure Assessment (SOFA) score. The score ranges from 0 to 24 points, where 0 indicates normal organ function and 24 represents severe multi-organ failure (higher scores indicate greater organ dysfunction and worse prognosis).
Time frame: Baseline (at ICU admission)
Ran from Jul 2026 to primary completion in Aug 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital H+ Queretaro